Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe
Sandoz, the Novartis generics and biosimilars division, is pleased to announce plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe.
Sandoz CEO Richard Saynor said: “This plan is a g ... more
Novartis to invest $75 million in start-up Poseida
Poseida Therapeutics Inc. announced closing of a Series C financing round, raising $142 million led by a $75 million equity investment from Novartis Pharma AG, and joined by several new investors including Aisling Capital Management, Pentwater Capital Management, Perceptive Advisors as well ... more
Novartis announces change in Sandoz leadership
Novartis announced that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrieri, currently Region Head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will repor ... more